A research study published in the journal Pharmacognosy Review of 2007 indicated that, in the developing countries around the world, more than 80% of the population is receiving medical or healthcare treatments based mainly on botanical drugs and traditional medicines. A number of German clinical studies have shown that the botanical drugs are not only equally effective as synthetic medicines, but do not have the side effects of the synthetic medicines. As a result, botanical drugs have become the main choice for medical treatments in Germany, and currently take up USD$40 billion in the global market. When treating immune system diseases, it is necessary to regulate and maintain balance among different immune system-related cells, cytokines, antibodies, and a number of body organs in order to treat or relieve symptoms of the diseases. Clinical studies have revealed that the botanical drugs have attributes capable of providing multiple-target mechanisms needed for treating the immune system diseases. Following the Western standards and specifications for developing new drugs, Medigreen Biotechnology Corp. is currently focusing on immune system-based researches, and developing botanical drugs aimed to serve as anti-asthma drugs, cancer adjunctive therapies, and anti-digestive ulcer drugs, which takes advantage of the botanical drugs global developmental trend, and the enormous market opportunity.

 
The CA-88 is a new anticancer botanical adjuvant drug: it is against the side effect of low immunology and life quality of the patients due to the chemotherapy and radiotherapy, through CA-88, the immunology is increased and the effect of life quality is improved, helping the cancer patients to receive complete chemotherapy and radiotherapy, in order to increase the cure effect of cancer, as well as to improve the life quality of the cancer patents.
 
MIC-31 is a new drug of new anti-ulcer mechanism of the digestive tract, it is purely natural, and does not contain any antibiotics or ant acids. Most stomach ulcer, stomach cancer and duodenal ulcer are all related to the Helicobacter pylori. The MIC-31 can prevent and cure the ulcer of digestive tract caused by the Helicobacter pylori. or alcohol, reducing the occurrence of diseases such as gastric hemorrhage caused by ulcer as well as gastric cancer...
 
1217B is the first one botanical anti-asthma drug in Asia which has passed IND of the FDA, at the same time; it also has successfully obtained the IND approval of the Department of Health for a new botanical anti-asthma drug with multi-target mechanism. The asthma is an allergic disease, after having contact with the allergen, the immunologic system of the human body would cause a series of inflammatory and allergic reactions. 1217B can inhibit the cytokine and bronchus contractions produced by these reactions, in order to reach the effect, to mild and to control the asthma...
 
 
 
 
 
 
  The current trend of advocating the labeling of health claims on health food products by advanced countries that include the U.S., European countries, Canada and Singapore is approached with the request of “No Scientific Evidence, No Health Claim.” The formulations of the functional products developed by Medigreen Biotechnology Corp., such as the healthy weight management formulation (MT4), the anti-allergy formulation (MAF), the anti-cancer adjuvant (LeukoUp), and the anti-digestive ulcer formulation (HF-899) have been scientifically approved by using the latest R&D platforms for new drug development, and supported by comprehensive experimental data, which satisfies the requirement of “Evidence-based Claim” for health foods in numerous countries. Therefore, using the functional products from Medigreen Biotechnology Corp. for entering the international health food market has its advantages, including the reduction of time and costs for product development, timely access to market opportunities, and possession of marketing advantages because the products meet the requirements of health claim or may be applied as health foods on the basis of the comprehensive experimental data.  
     
The LeukoUp is the first formula which has completed the 105 subjects of double-blind clinical trial according to the “Assessment Method of Side Effects After Cancer Chemotherapy and Radiotherapy” promulgated by Taiwan’s Department of Health. The results of clinical trial by Chung Shan Medical University have shown that the LeukoUp has the effect of improving the immunologic ability and life quality of the cancer patients who have received chemotherapy and radiotherapy...
 
The Helicobacter pylori and alcohol are the main reasons which cause ulcer of the digestive tract. Many people are Helicobacter pylori carriers; most of them did not know of being infected by Helicobacter pylori due to no digestive ulcer symptoms. HF-899 is the formula developed on the basis of MIC-31. Besides of being possible to prevent and to cure digestive ulcer, it also has a good effect on the digestive tract health care and releasing symptoms of flatulence, stomach ache, halitosis, etc...
 
 
Asthma, allergic rhinitis and atopic dermatitis are all allergic diseases of immunologic disorders. The experiments have shown that by taking MAF it is possible to reduce the biochemical indicators related to the allergens, in order to reach the allergy preventive effect...
 
The MT4 is a weight loss product, developed on the design principle of the “healthy weight management”, which is most popular in Japan. The clinical trial has shown, after the use of one month, the weight is lost in 2-5 kg in average; the efficiency is over 82%. It can also reduce effectively the concentration of triglycerides and cholesterol L.D.L., in order to reach the goal of both health and weight losing at the same time...
 
Besides the development of new anticancer adjuvant drugs, drugs against ulcer of digestive tracts and asthma, Medigreen Biotechnology Corp. also devotes itself to the development of drugs related to reduction of blood lipid, increase of the men’s sexual function, release of menstrual cramps, etc...